2025-12-28 - Analysis Report
Okay, here's a comprehensive analysis of Natera Inc. (NTRA) based on the provided data.

**1) Return Rate Comparison & Alpha/Beta Analysis**

*   **Company Overview:** Natera Inc. is a diagnostics company focusing on cell-free DNA testing.
*   **Return Rates:**
    *   NTRA Cumulative Return: 139.49%
    *   S&P 500 (VOO) Cumulative Return: 103.47%
    *   Divergence: 36.5
    *   Relative Divergence: 47.5

*   **Analysis:** NTRA has significantly outperformed the S&P 500 based on cumulative return. The divergence is currently positive. However, the relative divergence of 47.5 indicates that the current divergence is near the middle of its historical range.

*   **Alpha/Beta Analysis Table:**

    | Year       | CAGR    | MDD     | Alpha   | Beta   | Cap(B) |
    |------------|---------|---------|---------|--------|--------|
    | 2015-2017  | -10.0%  | 70.1%   | -34.0%  | -0.2   | 1.2    |
    | 2016-2018  | 22.0%   | 80.0%   | 6.0%    | 0.1    | 1.9    |
    | 2017-2019  | 50.0%   | 80.0%   | 28.0%   | 1.0    | 4.7    |
    | 2018-2020  | 186.0%  | 80.5%   | 163.0%  | 1.1    | 13.9   |
    | 2019-2021  | 96.0%   | 80.5%   | 49.0%   | 1.6    | 13.0   |
    | 2020-2022  | -77.0%  | 80.5%   | -76.0%  | 0.1    | 5.6    |
    | 2021-2023  | -194.0% | 76.6%   | -195.0% | -1.1   | 8.7    |
    | 2022-2024  | 8.0%    | 76.6%   | -13.0%  | -1.2   | 22.1   |
    | 2023-2025  | 167.0%  | 76.6%   | 99.0%   | 0.1    | 32.6   |

*   **Alpha/Beta Analysis Interpretation:**
    *   **CAGR:**  Shows a wide range of annual growth, including significant positive and negative years.
    *   **MDD:**  Maximum Drawdown is consistently high, indicating substantial risk.
    *   **Alpha:** The alpha values are highly variable, indicating NTRA's performance independent of the market (S&P 500) has been inconsistent.  Positive alpha means outperformance, negative means underperformance.
    *   **Beta:**  Beta fluctuates around 1, suggesting NTRA's volatility is generally similar to the market, but with periods of both higher and lower correlation. Negative betas in recent periods are unusual and suggest an inverse relationship with the market.
    *   **Cap(B):** Market capitalization shows growth, but with volatility alongside stock performance fluctuations.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 233.74
*   **Previous Close:** 235.54
*   **Change:** -0.76
*   **5-day SMA:** 234.442
*   **20-day SMA:** 234.3715
*   **60-day SMA:** 208.4035

*   **Analysis:** The stock price experienced a minor decrease in the last market day. The 5-day and 20-day Simple Moving Averages (SMAs) are very close, suggesting a period of consolidation. The 60-day SMA is significantly lower, indicating an upward trend over the past two months.

**3) RSI, PPO, and Expected Return Analysis**

*   **Market Risk Indicator (MRI):** 1.0 (High Investment Recommended)
*   **RSI:** 34.36 (Approaching Oversold)
*   **PPO:** -0.61 (Bearish)
*   **Hybrid Signal:** Buy 100% of cash (4 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent Divergence Change:** -0.1 (Short-term Decrease)
*   **Expected Return:** -49.9%

*   **Analysis:**
    *   **MRI:** Signals a high investment recommendation based on the model's risk assessment.
    *   **RSI:** Suggests the stock is nearing oversold conditions, potentially indicating a buying opportunity in the short term.
    *   **PPO:**  A negative PPO indicates a bearish trend in the short term.
    *   **Hybrid Signal:** The hybrid signal recommends a full investment of available cash, labeling it as "very safe".
    *   **Recent Divergence Change:**  Confirms short-term negative momentum.
    *   **Expected Return:** This is a *very* concerning figure.  A -49.9% expected return suggests the model anticipates significant underperformance over the next two years. This warrants further investigation.

**4) Recent News & Significant Events**

*   **Summary of Headlines:**
    *   **Institutional Investment:** SWS Partners bought shares of NTRA. This suggests institutional confidence in the stock.
    *   **Expert Opinion:**  A well-known investor is buying the stock. This might attract more investors.
    *   **Conference Presentation:** Natera is presenting at a health conference, potentially unveiling new data or strategies.
    *   **Positive Sentiment:** Some analysts find the stock appealing for multiple reasons.
    *   **Hold Rating:**  One analyst recommends a "Hold" rating despite growth in certain areas and improved margins.
    *   **Triple Potential:**  Another analysis suggests significant upside potential.

*   **Analysis:** The news is mixed. There's positive news regarding institutional investment, expert opinion, and potential upside. However, the "Hold" rating tempers enthusiasm.  The conference presentation could be a catalyst for positive movement if new information is well-received.

**4-2) Analyst Opinions**

*   **Consensus:** Strong Buy (1.47 on a 1-5 scale) based on 19 opinions.
*   **Target Price:** Average $246.26, High $285.00, Low $186.00

*   **Analysis:**  The analyst consensus is very bullish, with a Strong Buy recommendation and a target price significantly above the current price. However, the wide range between the high and low target prices indicates uncertainty among analysts.

**5) Recent Earnings Analysis**

| Date       | EPS   | Revenue    |
|------------|-------|------------|
| 2025-11-07 | -0.64 | 0.59 B$    |
| 2025-08-08 | -0.74 | 0.55 B$    |
| 2025-05-09 | -0.50 | 0.50 B$    |
| 2024-11-12 | -0.26 | 0.44 B$    |
| 2025-11-07 | -0.26 | 0.44 B$    |

*   **Analysis:**  While revenue is growing consistently, the company is still reporting negative Earnings Per Share (EPS). This suggests Natera is investing heavily in growth, which is impacting profitability. This is a common characteristic of growth stocks, but it's important to monitor the rate of cash burn.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue  | Profit Margin |
|--------------|----------|----------------|
| 2025-09-30   | $0.59B   | 64.91%         |
| 2025-06-30   | $0.55B   | 63.41%         |
| 2025-03-31   | $0.50B   | 63.12%         |
| 2024-12-31   | $0.48B   | 62.94%         |
| 2024-09-30   | $0.44B   | 61.79%         |

**Capital and Profitability:**

| Quarter      | Equity   | ROE     |
|--------------|----------|---------|
| 2025-09-30   | $1.25B   | -6.99%  |
| 2025-06-30   | $1.25B   | -8.10%  |
| 2025-03-31   | $1.24B   | -5.40%  |
| 2024-12-31   | $1.20B   | -4.50%  |
| 2024-09-30   | $0.88B   | -3.60%  |

*   **Analysis:**
    *   **Revenue:**  Consistent revenue growth quarter over quarter is a positive sign.
    *   **Profit Margin:**  The high and increasing profit margin is also positive, indicating improving efficiency.
    *   **Equity:**  Equity is relatively stable, indicating the company is managing its capital effectively.
    *   **ROE:**  The negative Return on Equity (ROE) reflects the company's ongoing losses. While improving, it remains a concern.

**7) Comprehensive Analysis (Summary)**

Natera Inc. (NTRA) presents a mixed picture:

*   **Positives:**
    *   Significant historical outperformance compared to the S&P 500.
    *   Strong revenue growth and increasing profit margins.
    *   Positive analyst consensus with a Strong Buy rating and high target price.
    *   Institutional investment and potential catalysts from conference presentations.
    *   Approaching oversold RSI, potentially indicating a short-term buying opportunity.

*   **Negatives:**
    *   High Maximum Drawdown, indicating significant risk.
    *   Negative EPS and ROE, indicating ongoing losses despite revenue growth.
    *   Negative Expected Return, suggesting potential underperformance in the future.
    *   Mixed news sentiment with some analysts recommending a "Hold" rating.
    *   Recent negative divergence change indicating short-term downward momentum.

**Conclusion:**

Natera is a high-growth, high-risk stock. The positive analyst sentiment and revenue growth are encouraging. However, the negative profitability metrics and alarming expected return are serious concerns. Investors should carefully weigh the potential rewards against the significant risks before investing in NTRA. Pay close attention to upcoming earnings reports and company announcements to assess the company's progress towards profitability and the validity of the negative expected return signal. The high MRI suggests the model views this as a safe time to invest, however, there are strong signals to the contrary. This warrants further investigation.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.